Editas Medicine said the USPTO reaffirmed an earlier Patent Trial and Appeal Board (PTAB) decision supporting Broad Institute inventorship priority for foundational CRISPR/Cas9 genome-editing patents. The decision follows a 2024 Court of Appeals for the Federal Circuit action that remanded the matter, criticizing the PTAB for conflating legal standards for conception and reduction to practice. Editas emphasized that its license arrangement includes Broad patents covering fundamental CRISPR/Cas9 and CRISPR/Cas12a editing aspects, and said other licensed patents were not affected by the interference outcome. The company tied the reaffirmation to confidence around its in vivo gene editing platform, including its EDIT-401 program. For the sector, the outcome matters less for clinical timelines and more for IP certainty that drives partner selection, investment and whether future therapies face litigation risk. CRISPR landscape disputes continue to set the terms for who can operate in specific editing modalities and jurisdictions. Companies will likely watch for next legal steps, especially if other parties pursue further appeals or additional challenges to the underlying priority framework.